Inactive Instrument

Highlights Checkmate Pharmaceuticals, Inc.

Equities

CMPI

US1628181083

Highlights

Unlock all the news: Be the first to know and act before the market!

Regeneron Completes Checkmate Pharmaceuticals Deal, Triggers $5 Million Milestone Payment to Kuros Biosciences	22-06-02	MT
Kuros To Receive $5 Million Milestone Payment from Regeneron's Acquisition Of Checkmate	22-06-02	MT
Regeneron Pharmaceuticals, Inc. completed the acquisition of Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others.	22-05-26	CI
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology Annual Meeting	22-05-26	CI
Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Checkmate Pharmaceuticals Shares Take Flight on Regeneron Deal	22-04-19	DJ
Regeneron to Buy Checkmate Pharmaceuticals for About $250 Million	22-04-19	DJ
Regeneron Pharmaceuticals Agrees to Buy Checkmate Pharmaceuticals in $250 Million All-Cash Deal	22-04-19	MT
Regeneron Pharmaceuticals, Inc. entered into a definitive agreement to acquire Checkmate Pharmaceuticals, Inc. from Decheng Capital China Life Sciences USD Fund III, L.P., a fund managed by Decheng Capital LLC, Arthur Krieg and others for approximately $250 million.	22-04-18	CI
Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research Annual Meeting	22-04-08	CI
Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
Checkmate Pharmaceuticals, Inc. Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using Vidutolimod	21-12-20	CI
Checkmate Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Checkmate Pharmaceuticals Presents Final Clinical Data for Phase 1B Study Evaluating Vidutolimod At the Society for Immunotherapy of Cancer 36Th Annual Meeting	21-11-12	CI
Checkmate Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2021	21-08-12	CI
Kuros Biosciences : Enters Royalty Purchase Deal With US-Based Xoma	21-07-15	MT
Checkmate Pharmaceuticals, Inc. Provides Update on Recent Progress	21-05-13	CI
Checkmate Pharmaceuticals, Inc. Reports Unaudited Earnings Result for the First Quarter Ended March 31, 2021	21-05-13	CI
Checkmate Pharmaceuticals, Inc. Announces Clinical Supply Agreement with Regeneron Pharmaceuticals, Inc. to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo®	21-05-10	CI
Checkmate Pharmaceuticals, Inc. Announces Initiation of Patient Dosing in Potential Registration Trial of Vidutolimod in Patients with Anti-PD-1 Refractory Advanced Melanoma	21-05-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Checkmate Pharmaceuticals, Inc.

Equities

CMPI

US1628181083

Highlights

Filters